Ticker

Only Abbott offers a complete screening solution combining end-to-end support with both stool- and blood-based colorectal cancer screening options, giving healthcare providers more ways to help eligible patients get screened1-3 SimpleScreen CRC expands screening options for adults age 45 and older, providing another way to help reach people who otherwise may remain unscreened SimpleScreen CRC is covered by Medicare,…

California Resources (NYSE: CRC - Get Free Report) and Kinetik (NYSE: KNTK - Get Free Report) are both mid-cap energy companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership. Volatility and Risk California Resources has a beta

Freenome is rated Buy, leveraging FDA-approved SimpleScreen CRC and a $410M cash reserve to target the vast unscreened colorectal market. FRNM's SimpleScreen CRC, now out-licensed to Abbott, offers a patient-friendly, blood-based alternative, with up to $700M in milestone payments and 10% royalties. Upcoming catalysts include the pivotal PROACT LUNG study for SimpleScreen Lung, which could validate the multiomics…

CRC plans to sell its non-core Uinta Basin assets for about $90 million, freeing cash to support its California-focused strategy and capital allocation.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Hu